Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Nesyrgy combines a calcium‑channel blocker with a β1‑selective blocker to address elevated blood pressure within the antihypertensive therapeutic class.

• Hypertension (essential): lowers systolic and diastolic blood pressure, improving overall cardiovascular risk profile in adult patients.
• Isolated systolic hypertension: provides greater reduction of systolic pressure, beneficial for older adults with stiff arteries.
• High‑risk hypertension: adds vasodilatory nitric‑oxide effect, aiding patients with additional cardiovascular risk factors.

• Amlodipine besilate blocks L‑type calcium channels in vascular smooth muscle, causing arterial dilation and reduced peripheral resistance. Nebivolol hydrochloride selectively antagonizes β1‑adrenergic receptors, decreasing heart rate and myocardial contractility, while simultaneously stimulating endothelial nitric‑oxide synthase to promote vasodilation. The combined actions result in synergistic lowering of blood pressure through decreased cardiac output and lowered systemic vascular tone through complementary pharmacodynamic pathways.

The most frequently reported adverse reactions with Nesyrgy are generally mild and related to its vasodilatory and β‑blockade properties.

Common Side Effects

• Headache: mild to moderate headache occurring during early therapy.
• Peripheral edema: swelling of ankles or lower legs due to fluid accumulation.
• Flushing: transient warmth and redness of the skin.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Fatigue: general tiredness or reduced energy levels.
• Palpitations: awareness of heartbeat irregularities.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Bradycardia: abnormally slow heart rate that may require medical attention.
• Heart block: impairment of electrical conduction in the heart.
• Hepatic dysfunction: elevated liver enzymes indicating possible liver injury.
• Angioedema: swelling of face, lips, tongue or throat that can compromise airway.
• Myocardial infarction: rare occurrence of heart attack during treatment.

Before initiating Nesyrgy, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Blood pressure monitoring: check baseline and periodic readings to assess efficacy.
• Cardiac function assessment: evaluate heart rate and conduction, especially in patients with bradycardia risk.
• Hepatic impairment caution: adjust use in patients with liver disease due to metabolism considerations.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Concomitant antihypertensives: avoid excessive blood pressure lowering when combined with other agents.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nesyrgy may interact with other medicines, altering its blood‑pressure‑lowering effect or increasing the risk of adverse events.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise amlodipine levels, causing excessive hypotension.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil): additive cardiac depression and bradycardia.
• Concomitant β‑blockers: risk of profound bradycardia and heart block.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine): can increase nebivolol concentrations.
• NSAIDs (e.g., ibuprofen): may blunt antihypertensive response.
• Alcohol: enhances vasodilatory effects, increasing dizziness.